OncoMatch/Clinical Trials/NCT05338931
Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Is NCT05338931 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies AT101(Anti-CD19 Chimeric Antigen Receptor T cell) for b-cell non hodgkin lymphoma.
Treatment: AT101(Anti-CD19 Chimeric Antigen Receptor T cell) — Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy or radiotherapy
Exception: excluding lymphodeletion
Those who have received chemotherapy or radiotherapy, excluding lymphodeletion, within two weeks prior to IP administration
Lab requirements
Blood counts
adequate hematological and bone marrow function without blood transfusion within two weeks prior to screening
Kidney function
adequate kidney function without blood transfusion within two weeks prior to screening
Liver function
adequate liver function without blood transfusion within two weeks prior to screening
Cardiac function
adequate heart function without blood transfusion within two weeks prior to screening
adequate hematological, kidney, liver, lung, heart and bone marrow function without blood transfusion within two weeks prior to screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05338931 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy or radiotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages